Prognostic and predictive biomarkers in renal cell carcinoma

Targeted Oncology

Volumn 5, Issue 2, 2010, Pages 85-94

  Vickers, Michael M ^a   Heng, Daniel Y C ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Biomarkers; Carbonic anhydrase IX (CAIX); Hypoxia inducible factor (HIF); Renal cell carcinoma; Vascular endothelial growth factor (VEGF); Von Hippel Lindau (VHL)

Indexed keywords

BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; S6 KINASE; SORAFENIB; SUNITINIB; SURVIVIN; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN;

CAPILLARY LEAK SYNDROME; CLINICAL TRIAL; DOSE RESPONSE; DRUG MEGADOSE; DRUG RESPONSE; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TREATMENT OUTCOME;

ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MUTATION; PATHOLOGY, MOLECULAR; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 77958019531     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-010-0143-8     Document Type: Review

References (77)

1. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
2. Lam JS, Shvarts O, Leppert JT et al (2005) Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 173:1853-1862
3. Janzen NK, Kim HL, Figlin RA et al (2003) Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin N Am 30:843-852
4. Kaelin WG Jr (2007) The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 13:680s-684s
5. Brugarolas J (2007) Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med 356:185-187
6. Sturgeon CM, Hoffman BR, Chan DW et al (2008) National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem 54: e1-e10
7. National Cancer Institute Dictionary of Cancer Terms. http://www.cancer.gov/dictionary/; accessed March 15, 2010
8. Kattan MW, Reuter V, Motzer RJ et al (2001) A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166:63-67
9. Leibovich BC, Blute ML, Cheville JC et al (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97:1663-1671
10. Patard JJ, Kim HL, Lam JS et al (2004) Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 22:3316-3322
11. Motzer RJ, Bacik J, Schwartz LH et al (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454-463
12. Cowey CL, Rathmell WK (2009) VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep 11:94-101
13. Brauch H, Weirich G, Brieger J et al (2000) VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 60:1942-1948
14. Schraml P, Struckmann K, Hatz F et al (2002) VHL mutations and their correlation with tumour cell proliferation, micro vessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 196:186-193
15. Patard JJ, Fergelot P, Karakiewicz PI et al (2008) Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 123:395-400
16. Yao M, Yoshida M, Kishida T et al (2002) VHL tumor suppressor gene alterations associated with good prognosis in sporadic clearcell renal carcinoma. J Natl Cancer Inst 94:1569-1575
17. Kondo K, Yao M, Yoshida M et al. (2002) Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosom Cancer 34:58-68
18. Gimenez-Bachs JM, Salinas-Sanchez AS, Sanchez-Sanchez F et al (2006) Determination of vhl gene mutations in sporadic renal cell carcinoma. Eur Urol 49:1051-1057
19. Smits KM, Schouten LJ, van Dijk BA et al (2008) Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis. Clin Cancer Res 14:782-787
20. Baldewijns MM, van Vlodrop IJ, Smits KM et al (2009) Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene. Cell Oncol 31:371-382
21. Kim JH, Jung CW, Cho YH et al (2005) Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep 13:859-864
22. Choueiri TK, Vaziri SA, Jaeger E et al (2008) von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 180:860-865
23. Gad S, Sultan-Amar V, Meric J et al (2007) Somatic von Hippel-Lindau (VHL) gene analysis and clinical outcome under antiangiogenic treatment in metastatic renal cell carcinoma: preliminary results. Target Oncol 2:3-6
24. Cho D, Signoretti S, Dabora S et al (2007) Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 5:379-385
25. Lam JS, Leppert JT, Figlin RA et al (2005) Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 66:1-9
26. Jacobsen J, Rasmuson T, Grankvist K et al (2000) Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 163:343-347
27. Escudier B, Eisen T, Stadler WM et al (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312-3318
28. Negrier S, Chabaud S, Escudier B et al (2007) Serum level of vascular endothelial growth factor (VEGF) as an independent prognostic factor in metastatic renal cell carcinoma (MRCC) [Abstract 5044]. J Clin Oncol 25:5044 [Available online at: http://meeting.ascopubs.org/cgi/content/Abstract/25/18- suppl/5044; cited March 15, 2010]
29. Escudier B, Ravaud A, Negrier S et al (2008) Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis [Abstract 5025]. J Clin Oncol 26:256s [Available online at: http://meeting.ascopubs.org/cgi/content/Abstract/ 26/15-suppl/5025; cited March 15, 2010]
30. Deprimo SE, Bello CL, Smeraglia J et al (2007) Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 5:32
31. Hutson TE, Davis ID, Machiels JH et al (2008) Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor [Abstract 5046]. J Clin Oncol 26:5046 [Available online at: http://meeting.ascopubs.org/cgi/ content/Abstract/26/15-suppl/5046; cited March 15, 2010]
32. Rini BI, Michaelson MD, Rosenberg JE et al (2008) Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26:3743-3748
33. Sabatino M, Kim-Schulze S, Panelli MC et al (2009) Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 27:2645-2652
34. Kim JJ, Vaziri SA, Elson P et al (2009) VEGF single nucleotide polymorphisms (SNPs) and correlation to sunitinib-induced hypertension (HTN) in metastatic renal cell carcinoma (mRCC) patients (pts) [Abstract 5005]. J Clin Oncol 27:5005 [Available online at: http://meeting.ascopubs.org/cgi/content/ Abstract/27/15S/5005; cited March 15, 2010]
35. Kim JJ, Vaziri SA, Elson P et al (2010) VEGF single nucleotide polymorphisms (SNPs) and correlation to baseline and sunitinibinduced hypertension (HTN) in patients (pts) with metastatic renal cell carcinoma (mRCC) [Abstract 330]. Genitourinary Cancers Symposium San Francisco. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst- detail-view&co nfID=73&AbstractID=30804; cited March 15, 2010].
36. Lidgren A, Hedberg Y, Grankvist K et al (2005) The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 11:1129-1135
37. Lidgren A, Hedberg Y, Grankvist K et al (2006) Hypoxiainducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray. Eur Urol 50:1272-1277
38. Klatte T, Seligson DB, Riggs SB et al (2007) Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 13:7388-7393
39. Dorevic G, Matusan-Ilijas K, Babarovic E et al (2009) Hypoxiainducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma. J Exp Clin Cancer Res 28:40
40. Raval RR, Lau KW, Tran MG et al (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25:5675-5686
41. Carroll VA, Ashcroft M (2006) Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 66:6264-6270
42. Covello KL, Simon MC, Keith B (2005) Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Res 65:2277-2286
43. Kondo K, Kim WY, Lechpammer M et al (2003) Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1: E83
44. Ivanov S, Liao SY, Ivanova A et al (2001) Expression of hypoxiainducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158:905-919
45. Liao SY, Aurelio ON, Jan K et al (1997) Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 57:2827-2831
46. McKiernan JM, Buttyan R, Bander NH et al (1997) Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma. Cancer Res 57:2362-2365
47. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ et al (1986) Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 38:489-494
48. McKiernan JM, Buttyan R, Bander NH et al (1999) The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. Cancer 86:492-497
49. Sandlund J, Oosterwijk E, Grankvist K et al (2007) Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 100:556-560 (Pubitemid 47205465)
50. Bui MH, Seligson D, Han KR et al (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9:802-811
51. Leibovich BC, Sheinin Y, Lohse CM et al (2007) Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 25:4757-4764
52. Li G, Feng G, Gentil-Perret A et al (2008) Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J Urol 180:510-513
53. Atkins M, Regan M, McDermott D et al (2005) Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11:3714-3721
54. de Martino M, Klatte T, Seligson DB et al (2009) CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. J Urol 182:728-734
55. Lam JS, Pantuck AJ, Belldegrun AS et al (2007) Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials. Clin Cancer Res 13:703s-708s
56. Peralba JM, DeGraffenried L, Friedrichs W et al (2003) Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9:2887-2892
57. Tanaka C, O'Reilly T, Kovarik JM et al (2008) Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 26:1596-1602
58. Thompson RH, Gillett MD, Cheville JC et al (2004) Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 101:17174-17179
59. Thompson RH, Gillett MD, Cheville JC et al (2005) Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer 104:2084-2091
60. Porta C, Paglino C, De Amici M et al (2010) Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int 77:809-815
61. Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296
62. Kim HL, Seligson D, Liu X et al (2005) Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 173:1496-501
63. Parker AS, Leibovich BC, Lohse CM et al (2009) Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer 115:2092-2103
64. Zisman A, Pantuck AJ, Dorey F et al (2001) Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19:1649-1657 (Pubitemid 32230864)
65. Frank I, Blute ML, Cheville JC et al (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168:2395-2400
66. Takahashi M, Rhodes DR, Furge KA et al (2001) Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA 98:9754-9759
67. Vasselli JR, Shih JH, Iyengar SR et al (2003) Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci USA 100:6958-6963
68. Kosari F, Parker AS, Kube DM et al (2005) Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 11:5128-5139
69. Sultmann H, von Heydebreck A, Huber W et al (2005) Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin Cancer Res 11:646-55
70. Jones J, Otu H, Spentzos D et al (2005) Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 11:5730-5739
71. Zhao H, Ljungberg B, Grankvist K et al (2006) Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med 3: e13
72. Kent OA, Mendell JT (2006) A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 25:6188-6196
73. Lu J, Getz G, Miska EA et al (2005) MicroRNA expression profiles classify human cancers. Nature 435:834-838
74. Gottardo F, Liu CG, Ferracin M et al (2007) Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 25:387-392
75. Nakada C, Matsuura K, Tsukamoto Y et al (2008) Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol 216:418-427
76. Juan D, Alexe G, Antes T et al (2010) Identification of a MicroRNA panel for Clear-cell kidney cancer. Urology 75:835-841
77. Chow TF, Youssef YM, Lianidou E et al (2010) Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem 43:150-158